XINGYU MEI, ZHOUWEI WU, CHENGZHONG ZHANG, YUE SUN, WEIMIN SHI^*

BIOCELL, Vol.45, No.6, pp. 1551-1559, 2021, DOI:10.32604/biocell.2021.015376 - 01 September 2021

Abstract Vitiligo results in an autoimmune disorder destructing skin pigment cells, melanocytes (Mcs). This study aimed to investigate whether Astragaloside IV (AIV) could efficiently induce differentiation of bone marrow mesenchymal stem cells (BMMSCs) into Mcs. BMMSCs were induced and differentiated into Mcs with 0.1, 0.2, and 0.4 mg/L AIV during 150-day. Morphologic changes of differentiated cells were observed. Levels of some melanocytic specific genes (TRP-1, TRP-2, MART-1, Mitf) were measured with quantitative polymerase chain reaction (qPCR) at 90, 120, and 150 days of induction. After 90-day induction, the differentiated cells with 0.4 mg/L AIV demonstrated the typical morphology… More >

Liwei Jia^*, Dongying Lv^†, Shuang Zhang^*, Zhenyue Wang^*, Bo Zhou^*

Oncology Research, Vol.27, No.4, pp. 503-508, 2019, DOI:10.3727/096504018X15344989701565

Abstract Astragaloside IV (AS-IV) is an active ingredient in Astragalus membranaceus and is involved in various biological processes, such as regulating the immune system, and counteracting inflammation and malignancy. The aim of this study was to explore the effect of AS-IV on non-small cell lung cancer (NSCLC) cells. Cell counting kit (CCK)-8 assay and flow cytometry were performed to investigate cell survival and cell death, and Western blotting was performed to assess protein expression. We found that AS-IV inhibited the migration and proliferation of NSCLC cells and caused a noticeable increase in cell death. Furthermore, the More >

Tao Xie^*, Yao Li^†, Shi-Lei Li^*, Hai-Feng Luo^‡

Oncology Research, Vol.24, No.6, pp. 447-453, 2016, DOI:10.3727/096504016X14685034103590

Abstract Although astragaloside IV exhibits anti-inflammation, immunoregulatory, and anticancer properties, the chemosensitization effects of astragaloside IV in colorectal cancer have never been reported. Our study tested whether astragaloside could increase cisplatin sensitivity in colorectal cancer. CCK-8 assay was used to measure the cell viability of colorectal cancer cells. Quantitative real-time PCR and Western blot were performed to determine the mRNA and protein expression, respectively. Our data revealed that astragaloside IV administration significantly suppressed the cell growth of colorectal cancer cells, whereas no obvious cytotoxicity of astragaloside IV was observed in nonmalignant colonic cells. In addition, combined… More >